Recombinant-activated coagulation factor VIIa (NovoSeven®): current development

Recombinant activated coagulation factor VII (rFVIIa) was developed initially for treatment of patients with hemophilia and neutralizing antibodies (“inhibitors”) to coagulation factors VIII or IX. Owing to the unique and selective mechanism of action of rFVIIa and encouraged by clinical experience...

Full description

Saved in:
Bibliographic Details
Published in:Vox sanguinis 2007-05, Vol.92 (4), p.281-288
Main Author: Weiskopf, R. B.
Format: Article
Language:English
Subjects:
Blood Coagulation Disorders - drug therapy
Brain Injuries - drug therapy
Cerebral Hemorrhage - drug therapy
clinical trials
drug development
efficacy
Factor VII - therapeutic use
Factor VII Deficiency - drug therapy
Factor VIIa
Hemophilia A - drug therapy
Hemorrhage - drug therapy
hemostasis
Humans
intracerebral hemorrhage
mechanism of action
Postoperative Hemorrhage - drug therapy
Prospective Studies
Randomized Controlled Trials as Topic
recombinant activated coagulation factor VII (rFVIIa)
Recombinant Proteins - therapeutic use
Safety
surgery
Thrombasthenia - drug therapy
trauma
Wounds and Injuries - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recombinant activated coagulation factor VII (rFVIIa) was developed initially for treatment of patients with hemophilia and neutralizing antibodies (“inhibitors”) to coagulation factors VIII or IX. Owing to the unique and selective mechanism of action of rFVIIa and encouraged by clinical experience with other circumstances of inadequate hemostasis, a broad development program has been pursued to test potential efficacy and evaluate safety of this biologic for indications other than hemophilia. This review summarizes the current development of rFVIIa, focusing on results of prospective, randomized clinical trials.
ISSN:0042-9007
1423-0410
DOI:10.1111/j.1423-0410.2006.00888.x